Long term adjuvant therapy for primary breast cancer.
作者信息
Bulbrook R D
出版信息
BMJ. 1996 Feb 17;312(7028):389-90. doi: 10.1136/bmj.312.7028.389.
Abstract
摘要
相似文献
1
Long term adjuvant therapy for primary breast cancer.
BMJ. 1996 Feb 17;312(7028):389-90. doi: 10.1136/bmj.312.7028.389.
2
Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
J Clin Oncol. 2005 Aug 1;23(22):4850-2. doi: 10.1200/JCO.2005.03.904. Epub 2005 Jul 11.
3
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Cochrane Database Syst Rev. 2008 Oct 8(4):CD004562. doi: 10.1002/14651858.CD004562.pub3.
4
Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
J Clin Oncol. 2009 Dec 10;27(35):e255-6; author reply e257-8. doi: 10.1200/JCO.2009.25.3914. Epub 2009 Nov 2.
5
Efficacy of tamoxifen as treatment of breast cancer.
Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-48-S1-54.
6
Should adjuvant chemotherapy be used in elderly women (> or = 70 years) with breast cancer? Contra.
Tumori. 2002 Jan-Feb;88(1 Suppl 1):S91-2. doi: 10.1177/030089160208800128.
7
LHRH-agonist versus chemotherapy in premenopausal breast cancer?
Eur J Cancer. 2002 Nov;38 Suppl 6:S45-6. doi: 10.1016/s0959-8049(02)00282-4.
8
Adjuvant tamoxifen: how long before we know how long?
BMJ. 1998 May 16;316(7143):1518-9. doi: 10.1136/bmj.316.7143.1518.
9
[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Ugeskr Laeger. 2007 Jan 22;169(4):297-9.
10
Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst. 2002 Oct 2;94(19):1504. doi: 10.1093/jnci/94.19.1504.
引用本文的文献
1
Management of primary breast cancer.
Qual Health Care. 1996 Dec;5(4):250-8. doi: 10.1136/qshc.5.4.250.
2
Adjuvant treatment with tamoxifen. Informed consent and follow up in aTTom trial are inadequate.
BMJ. 1996 Aug 24;313(7055):494. doi: 10.1136/bmj.313.7055.494.
3
Adjuvant treatment with tamoxifen. Care is necessary.
BMJ. 1996 Aug 24;313(7055):493-4. doi: 10.1136/bmj.313.7055.493c.
4
Adjuvant treatment with tamoxifen. Multicentre trial should be welcomed.
BMJ. 1996 Apr 20;312(7037):1037. doi: 10.1136/bmj.312.7037.1037.
5
Adjuvant treatment with tamoxifen. Clinicians must share knowledge with their patients more readily.
BMJ. 1996 Apr 20;312(7037):1037. doi: 10.1136/bmj.312.7037.1037a.
6
Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue.
BMJ. 1996 Apr 20;312(7037):1036-7. doi: 10.1136/bmj.312.7037.1036b.
7
Adjuvant treatment with tamoxifen. Side effects may have been overstated.
BMJ. 1996 Apr 20;312(7037):1036. doi: 10.1136/bmj.312.7037.1036.
8
Adjuvant treatment with tamoxifen. Local research ethics committees should review their approval of prevention trial.
BMJ. 1996 Apr 20;312(7037):1036. doi: 10.1136/bmj.312.7037.1036a.
本文引用的文献
1
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
J Clin Oncol. 1996 Jan;14(1):78-84. doi: 10.1200/JCO.1996.14.1.78.
2
A risk-benefit assessment of tamoxifen therapy.
Drug Saf. 1993 May;8(5):381-97. doi: 10.2165/00002018-199308050-00005.
3
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.
J Clin Oncol. 1993 Nov;11(11):2090-100. doi: 10.1200/JCO.1993.11.11.2090.
4
Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.
J Natl Cancer Inst. 1995 May 3;87(9):645-51. doi: 10.1093/jnci/87.9.645.
5
Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy.
Cancer. 1990 Jul 15;66(2):199-205. doi: 10.1002/1097-0142(19900715)66:2<199::aid-cncr2820660202>3.0.co;2-l.
6
Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group.
Acta Oncol. 1992;31(2):251-7. doi: 10.3109/02841869209088911.
Zotero 插件